

Georg Maschmeyer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8319570/publications.pdf>

Version: 2024-02-01

78
papers

9,413
citations

87723

38
h-index

58464

82
g-index

91
all docs

91
docs citations

91
times ranked

9354
citing authors

#	ARTICLE	IF	CITATIONS
1	Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. <i>Clinical Infectious Diseases</i> , 2008, 46, 1813-1821.	2.9	4,375
2	Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2016, 27, v111-v118.	0.6	454
3	Invasive Aspergillosis. <i>Drugs</i> , 2007, 67, 1567-1601.	4.9	339
4	Antimicrobial therapy of unexplained fever in neutropenic patients. <i>Annals of Hematology</i> , 2003, 82, S105-S117.	0.8	233
5	ECIL guidelines for preventing <i>Pneumocystis jirovecii</i> pneumonia in patients with haematological malignancies and stem cell transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2397-2404.	1.3	211
6	Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. <i>Annals of Hematology</i> , 2016, 95, 1435-1455.	0.8	169
7	Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2018, 97, 197-207.	0.8	162
8	Clinical pharmacology of antifungal compounds. <i>Infectious Disease Clinics of North America</i> , 2003, 17, 159-191.	1.9	145
9	Treatment of invasive fungal infections in cancer patients—updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2014, 93, 13-32.	0.8	143
10	Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study. <i>Cancer</i> , 1994, 73, 2296-2304.	2.0	132
11	Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). <i>Leukemia</i> , 2019, 33, 844-862.	3.3	131
12	Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2017, 96, 1775-1792.	0.8	129
13	Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2009, 88, 97-110.	0.8	128
14	Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT) Tj ETQq0 0 0 rgBT /Overlock 10 Tf of Hematology and Medical Oncology (DGHO). <i>Annals of Oncology</i> , 2015, 26, 21-33.	0.6	121
15	Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. <i>European Journal of Cancer</i> , 2009, 45, 2462-2472.	1.3	115
16	Primary prophylaxis of bacterial infections and <i>Pneumocystis jirovecii</i> pneumonia in patients with hematological malignancies and solid tumors. <i>Annals of Hematology</i> , 2013, 92, 433-442.	0.8	112
17	Interventional antimicrobial therapy in febrile neutropenic patients. <i>Annals of Hematology</i> , 1994, 69, 231-243.	0.8	108
18	Diagnosis of invasive fungal infections in hematology and oncology—guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). <i>Annals of Oncology</i> , 2012, 23, 823-833.	0.6	99

#	ARTICLE	IF	CITATIONS
19	Review of the Incidence and Prognosis of Pseudomonas aeruginosa Infections in Cancer Patients in the 1990s. European Journal of Clinical Microbiology and Infectious Diseases, 2000, 19, 915-925.	1.3	98
20	Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Annals of Hematology, 2014, 93, 1449-1456.	0.8	88
21	Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology. Annals of Oncology, 2014, 25, 936-947.	0.6	87
22	Treatment of fungal infections in hematology and oncology. Annals of Hematology, 2003, 82, S133-S140.	0.8	79
23	Outcome analysis of 189 consecutive cancer patients referred to the intensive care unit as emergencies during a 2-year period. European Journal of Cancer, 2003, 39, 783-792.	1.3	78
24	Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplantation, 2001, 27, 525-529.	1.3	77
25	Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies. Annals of Hematology, 2003, 82, S175-S185.	0.8	77
26	Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. Journal of Antimicrobial Chemotherapy, 2008, 61, 939-946.	1.3	74
27	The changing epidemiology of invasive fungal infections: new threats. International Journal of Antimicrobial Agents, 2006, 27, 3-6.	1.1	70
28	Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (<sc>AGIHO</sc>). Mycoses, 2018, 61, 796-813.	1.8	69
29	Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumorsâ€”Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Annals of Oncology, 2018, 29, 1354-1365.	0.6	64
30	The epidemiology and treatment of infections in cancer patients. International Journal of Antimicrobial Agents, 2008, 31, 193-197.	1.1	63
31	Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an <i><sc>A</sc> spergillus </i> <sc>PCR</sc> assay and a galactomannan <sc>ELISA</sc> in bronchoalveolar lavage samples. European Journal of Haematology. 2012. 89. 120-127.	1.1	63
32	CNS infections in patients with hematological disorders (including allogeneic stem-cell) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 227 Td (tr of Hematology and Medical Oncology (DGHO). Annals of Oncology, 2016, 27, 1207-1225.	0.6	59
33	Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors. Annals of Hematology, 2003, 82, S186-S200.	0.8	56
34	Pneumonia in febrile neutropenic patients: radiologic diagnosis. Current Opinion in Oncology, 2001, 13, 229-235.	1.1	52
35	Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients. Annals of Hematology, 1998, 76, 73-80.	0.8	46
36	Antimicrobial therapy of febrile complications after high-dose chemo-/radiotherapy and autologous hematopoietic stem cell transplantation. Annals of Hematology, 2003, 82, S167-S174.	0.8	44

#	ARTICLE	IF	CITATIONS
37	Update on antifungal treatment of invasive Candida and Aspergillus infections. Derzeitiger Kenntnisstand in der antimykotischen Behandlung invasiver Candida- und Aspergillus-Infektionen. <i>Mycoses</i> , 2004, 47, 263-276.	1.8	42
38	Treatment of invasive fungal diseases in cancer patientsâ€”Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Mycoses</i> , 2020, 63, 653-682.	1.8	42
39	A Prospective, Randomized Multicenter Trial of the Empirical Addition of Antifungal Therapy for Febrile Neutropenic Cancer Patients: Results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II. <i>Infection</i> , 2006, 34, 118-126.	2.3	40
40	Primary prophylaxis of bacterial infections and <i>Pneumocystis jirovecii</i> pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). <i>Annals of Hematology</i> , 2021, 100, 1603-1620.	0.8	39
41	Update on management of infections in cancer and stem cell transplant patients. <i>Annals of Hematology</i> , 2006, 85, 345-356.	0.8	37
42	Diagnosis and antimicrobial therapy of pulmonary infiltrates in febrile neutropenic patients. <i>Annals of Hematology</i> , 2003, -1, 1-1.	0.8	36
43	Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial. <i>British Journal of Haematology</i> , 2005, 130, 265-270.	1.2	35
44	Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 983-995.	2.0	34
45	Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2021, 100, 321-336.	0.8	34
46	Management of infections during intensive treatment of hematologic malignancies. <i>Annals of Hematology</i> , 1997, 75, 9-16.	0.8	33
47	Our 2014 approach to breakthrough invasive fungal infections. <i>Mycoses</i> , 2014, 57, 645-651.	1.8	32
48	Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 446-450.	1.1	31
49	Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Oncology</i> , 2013, 24, 1189-1202.	0.6	29
50	Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. <i>Leukemia</i> , 2019, 33, 2710-2719.	3.3	28
51	A prospective, randomised study on the use of well-fitting masks for prevention of invasive aspergillosis in high-risk patients. <i>Annals of Oncology</i> , 2009, 20, 1560-1564.	0.6	26
52	Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin. <i>Mycoses</i> , 2005, 48, 227-234.	1.8	25
53	How to manage lung infiltrates in adults suffering from haematological malignancies outside allogeneic haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2016, 173, 179-189.	1.2	25
54	Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients. <i>Haematologica</i> , 2011, 96, 1855-1860.	1.7	22

#	ARTICLE	IF	CITATIONS
55	Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 679-689.	1.3	22
56	Invasive mould infections: a multi-disciplinary update. <i>Medical Mycology</i> , 2009, 47, 571-583.	0.3	21
57	Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections. <i>Future Microbiology</i> , 2006, 1, 365-385.	1.0	20
58	New antifungal agents—treatment standards are beginning to grow old. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 49, 239-241.	1.3	19
59	Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (IHS) and the European Leukemia Net (ELN). <i>Leukemia</i> , 2022, 36, 1215-1226.	3.3	19
60	Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108). <i>European Journal of Cancer</i> , 2019, 122, 53-60.	1.3	16
61	Interventional antimicrobial therapy in febrile neutropenic patients. <i>Diagnostic Microbiology and Infectious Disease</i> , 1999, 34, 205-212.	0.8	14
62	Defining clinical failure for salvage studies. <i>Medical Mycology</i> , 2006, 44, 315-318.	0.3	13
63	Prevention of mould infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, i27-i30.	1.3	11
64	New immunosuppressive agents and risk for invasive fungal infections. <i>Current Infectious Disease Reports</i> , 2009, 11, 435-438.	1.3	10
65	Invasive fungal disease: better survival through early diagnosis and therapeutic intervention. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 279-281.	2.0	7
66	What's new in diagnosis and antimicrobial therapy of febrile neutropenic patients with lung infiltrates?. <i>Intensive Care Medicine</i> , 2014, 40, 1549-1552.	3.9	7
67	Diagnosis and Antimicrobial Therapy of Lung Infiltrates in Febrile Neutropenic Cancer Patients. <i>Current Infectious Disease Reports</i> , 2011, 13, 510-516.	1.3	6
68	A retrospective review of diagnosis and treatment modalities of neuroendocrine tumors (excluding) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 and Oncology (OSHO), 2010–2012. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1639-1644.	1.2	6
69	The EHA Research Roadmap: Infections in Hematology. <i>HemaSphere</i> , 2021, 5, e662.	1.2	5
70	Reporting infectious complications in haematology clinical trials should be improved. <i>Clinical Microbiology and Infection</i> , 2019, 25, 1451-1453.	2.8	4
71	Changing patterns of infections and antimicrobial susceptibilities. <i>Oncology</i> , 2000, 14, 9-16.	0.4	3
72	Residual thymic tissue and lymph node involvement by acute myeloid leukaemia presenting as mediastinal, strongly FDG-PET positive masses. <i>European Journal of Haematology</i> , 2017, 99, 286-288.	1.1	2

#	ARTICLE	IF	CITATIONS
73	Challenges in Infectious Diseases for Haematologists. <i>Oncology Research and Treatment</i> , 2018, 41, 406-410.	0.8	2
74	Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID Trial. <i>Oncology Research and Treatment</i> , 2022, 45, 319-325.	0.8	1
75	Fever of Unknown Origin: Treatment According to Risk Assessment. , 2015, , 155-163.		0
76	Maintaining an Adult Hematology/Oncology Service at a Tertiary Care Center during the SARS-CoV-2 Pandemic: An Eight-Week-Experience with a Newly Implemented Procedural Plan. <i>Oncology Research and Treatment</i> , 2021, 44, 354-359.	0.8	0
77	Epidemiology of Respiratory Events in Patients with HM (Not Including ICU). , 2011, , 41-45.		0
78	Pulmonary Complications. , 2015, , 165-185.		0